BR0313555A - Aplicação de inibidores de ikb-cinase na terapia da dor - Google Patents

Aplicação de inibidores de ikb-cinase na terapia da dor

Info

Publication number
BR0313555A
BR0313555A BR0313555-1A BR0313555A BR0313555A BR 0313555 A BR0313555 A BR 0313555A BR 0313555 A BR0313555 A BR 0313555A BR 0313555 A BR0313555 A BR 0313555A
Authority
BR
Brazil
Prior art keywords
kinase inhibitors
application
pain therapy
ikb kinase
ikb
Prior art date
Application number
BR0313555-1A
Other languages
English (en)
Inventor
Martin Michaelis
Olaf Ritzeler
Gerhard Jaehne
Karl Rudolphi
Gerd Geisslinger
Hans-Georg Schaible
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR0313555A publication Critical patent/BR0313555A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Paper (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"APLICAçãO DE INIBIDORES DE IkB-CINASE NA TERAPIA DA DOR". Inibidores de I<sym>B-cinase prestam-se para a preparação de medicamentos para o tratamento de dores. Inibidores adequados são provenientes dos compostos da fórmula (I) e (Ia).
BR0313555-1A 2002-08-17 2003-08-05 Aplicação de inibidores de ikb-cinase na terapia da dor BR0313555A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10237723A DE10237723A1 (de) 2002-08-17 2002-08-17 Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
PCT/EP2003/008628 WO2004022057A1 (de) 2002-08-17 2003-08-05 VERWENDUNG VON IκB-KINASE INHIBITOREN IN DER SCHMERZTHERAPIE

Publications (1)

Publication Number Publication Date
BR0313555A true BR0313555A (pt) 2005-07-12

Family

ID=31968975

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0313555-1A BR0313555A (pt) 2002-08-17 2003-08-05 Aplicação de inibidores de ikb-cinase na terapia da dor

Country Status (34)

Country Link
EP (1) EP1531819B1 (pt)
JP (1) JP4504811B2 (pt)
KR (2) KR20110135428A (pt)
CN (1) CN100398107C (pt)
AR (1) AR043045A1 (pt)
AT (1) ATE418336T1 (pt)
AU (1) AU2003271555B2 (pt)
BR (1) BR0313555A (pt)
CA (1) CA2495455C (pt)
CO (1) CO5690585A2 (pt)
CR (1) CR7716A (pt)
CY (1) CY1108874T1 (pt)
DE (2) DE10237723A1 (pt)
DK (1) DK1531819T3 (pt)
EC (1) ECSP055609A (pt)
ES (1) ES2320118T3 (pt)
HK (1) HK1079426A1 (pt)
HR (1) HRP20050041B1 (pt)
IL (1) IL166780A (pt)
MA (1) MA27334A1 (pt)
MX (1) MXPA05001218A (pt)
MY (1) MY138059A (pt)
NO (1) NO334309B1 (pt)
OA (1) OA12907A (pt)
PL (1) PL212356B1 (pt)
PT (1) PT1531819E (pt)
RS (1) RS51878B (pt)
RU (1) RU2320338C2 (pt)
SI (1) SI1531819T1 (pt)
TN (1) TNSN05044A1 (pt)
TW (1) TWI325782B (pt)
UA (1) UA80837C2 (pt)
WO (1) WO2004022057A1 (pt)
ZA (1) ZA200500323B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1771169A1 (en) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
NZ553329A (en) 2004-07-22 2010-09-30 Ptc Therapeutics Inc Thienopyridines for treating hepatitis C
DE102005025225A1 (de) 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP5790440B2 (ja) 2010-12-01 2015-10-07 住友化学株式会社 ピリミジン化合物およびその有害生物防除用途
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2532755A1 (en) * 2011-06-10 2012-12-12 Sanofi-Aventis Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
SI2787998T1 (sl) * 2011-12-06 2017-02-28 Sanofi Kristalinične oblike 2-(2-metilamino-pirimidin-4-il)-1H-indol-5-karboksilne kisline ((S)-1- karbamoil-2-(fenil-pirimidin-2-il-amino)etil)-amida
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
JO3425B1 (ar) * 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
ES2697806T3 (es) * 2014-07-03 2019-01-28 Sanofi Sa [(S)-1-carbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida del ácido 2-(2-metilamino-pirimidin-4-il)-1H-indol-5-carboxílico para uso en el tratamiento de dolor asociado a artrosis
JP2021530505A (ja) 2018-07-16 2021-11-11 ノバルティス アーゲー フェニルピペリジニルインドール誘導体を調製する化学的プロセス

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ516348A (en) * 1999-06-23 2003-06-30 Aventis Pharma Gmbh Substituted benzimidazole
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase

Also Published As

Publication number Publication date
PL212356B1 (pl) 2012-09-28
ES2320118T3 (es) 2009-05-19
EP1531819B1 (de) 2008-12-24
MY138059A (en) 2009-04-30
EP1531819A1 (de) 2005-05-25
TW200417370A (en) 2004-09-16
PT1531819E (pt) 2009-02-18
SI1531819T1 (sl) 2009-06-30
CR7716A (es) 2008-11-25
KR20110135428A (ko) 2011-12-16
TNSN05044A1 (en) 2007-05-14
OA12907A (en) 2006-10-13
ATE418336T1 (de) 2009-01-15
DK1531819T3 (da) 2009-04-20
CY1108874T1 (el) 2014-07-02
ECSP055609A (es) 2005-04-18
HRP20050041B1 (hr) 2013-07-31
RS51878B (sr) 2012-02-29
WO2004022057A1 (de) 2004-03-18
DE10237723A1 (de) 2004-07-08
AU2003271555B2 (en) 2009-03-26
JP2005539053A (ja) 2005-12-22
IL166780A0 (en) 2006-01-15
IL166780A (en) 2011-11-30
HK1079426A1 (en) 2006-04-07
PL373568A1 (en) 2005-09-05
CO5690585A2 (es) 2006-10-31
CN100398107C (zh) 2008-07-02
MXPA05001218A (es) 2005-05-16
AR043045A1 (es) 2005-07-13
JP4504811B2 (ja) 2010-07-14
KR101119845B1 (ko) 2012-02-28
UA80837C2 (uk) 2007-11-12
AU2003271555A1 (en) 2004-03-29
DE50310980D1 (de) 2009-02-05
MA27334A1 (fr) 2005-05-02
RU2005107419A (ru) 2005-08-10
RU2320338C2 (ru) 2008-03-27
CN1674899A (zh) 2005-09-28
RS20050070A (en) 2007-06-04
NO20051339L (no) 2005-05-03
TWI325782B (en) 2010-06-11
HRP20050041A2 (hr) 2006-04-30
CA2495455C (en) 2011-01-11
KR20050058339A (ko) 2005-06-16
ZA200500323B (en) 2006-02-22
CA2495455A1 (en) 2004-03-18
NO334309B1 (no) 2014-02-03

Similar Documents

Publication Publication Date Title
BR0313555A (pt) Aplicação de inibidores de ikb-cinase na terapia da dor
SE0101387D0 (sv) Novel compounds
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
EA200501095A1 (ru) Фенилацетамиды и их применение в качестве модуляторов глюкокиназы
ATE449079T1 (de) Pharmazeutische zusammensetzungen beinhaltend kristallsalze von 7-ä4-(4-fluorophenyl)-6- isopropyl-2-
DE60239648D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Asthma
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
SE0301700D0 (sv) Novel compounds
DE60333294D1 (de) Kontrollierte verabreichung von arzneien
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
PL378107A1 (pl) 1,2,4-triazyny hamujące HIV
EA200800172A1 (ru) 2,4-диаминопиримидины как ингибиторы aurora
CL2004000409A1 (es) Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
DE50212273D1 (de) Pharmazeutische salze von 1-phenyl-3-dimethylamino-propan-verbindungen
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
RS41104A (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
RS51271B (sr) Čvrsta farmaceutska kompozicija koja sadrži donepezil hidrohlorid
EA200300334A1 (ru) Новая соль периндоприла и содержащие ее фармацевтические композиции
SE0302139D0 (sv) Novel compounds
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
SV2004001555A (es) Difenilazetidinonas cationicamente sustituidas, procesos para su preparacion, medicamentos que contienen estos compuestos y sus usos
DE50301661D1 (de) Darreichungsform von Ibuprofen-Natrium

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 13 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time